abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

CD34
Back
Total number of drugs
13
Phase II and later clinical stages
23.1%
Involving companies
15
Main therapeutic areas
Other Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
Stem cell therapeutics (ExCellThera)Stem cell therapeutics (ExCellThera)Hematopoietic stem cell therapyNeoplasms Hemic and Lymphatic Diseases Immune System Diseases Other DiseasesHematopoietic progenitor cell antigen CD34 agonists Stem cells stimulantsExCellThera, Inc.Cordex Biologics, Inc.ExCellThera, Inc.ApprovedEuropean Union Iceland Liechtenstein Norway2025-08-25United StatesStem cell therapeutics (ExCellThera)
detail  >
Lentiviral Gene Therapy(University of California, San Francisco)Lentiviral Gene Therapy(University of California, San Francisco)Gene therapyImmune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Other DiseasesHematopoietic progenitor cell antigen CD34 modulatorsThe University of California, San FranciscoThe University of California, San FranciscoPhase 1/2Lentiviral Gene Therapy(University of California, San Francisco)
detail  >
Retroviral ADA-transduced CD34+ cells(University of California, Los Angeles)Retroviral ADA-transduced CD34+ cells(University of California, Los Angeles)Gene therapyImmune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Other DiseasesHematopoietic progenitor cell antigen CD34 antagonistsUniversity of California, Los AngelesUniversity of California, Los AngelesPhase 1/2Retroviral ADA-transduced CD34+ cells(University of California, Los Angeles)
detail  >
Autologous CD34+ cells transduced with TNS9.3.55(San Rocco Therapeutics)Autologous CD34+ cells transduced with TNS9.3.55(San Rocco Therapeutics)Hematopoietic stem cell therapyCongenital Disorders Hemic and Lymphatic Diseases Other DiseasesHematopoietic progenitor cell antigen CD34 modulatorsSan Rocco TherapeuticsSan Rocco TherapeuticsPhase 1Autologous CD34+ cells transduced with TNS9.3.55(San Rocco Therapeutics)
detail  >
HSC-100HSC-100Hematopoietic stem cell therapyNeoplasms Hemic and Lymphatic DiseasesHematopoietic progenitor cell antigen CD34 modulators Cell replacementsTatcitus TherapeuticsThe Mount Sinai Health System, Inc.Tatcitus TherapeuticsPhase 1HSC-100
detail  >
CN118703442CN118703442Cell therapyHemic and Lymphatic DiseasesDiscoveryCN118703442
detail  >
Wiskott-Aldrich Syndrome therapy (ImmunoVec)Wiskott-Aldrich Syndrome therapy (ImmunoVec)Gene therapyImmune System Diseases Congenital Disorders Hemic and Lymphatic Diseases Other DiseasesHematopoietic progenitor cell antigen CD34 modulatorsImmunoVec, Inc.ImmunoVec, Inc.DiscoveryUnited StatesWiskott-Aldrich Syndrome therapy (ImmunoVec)
detail  >
CD34-mdr1 gene therapy(University of Michigan College of Engineering)CD34-mdr1 gene therapy(University of Michigan College of Engineering)Gene therapyNeoplasmsHematopoietic progenitor cell antigen CD34 agonistsUniversity of Michigan College of EngineeringDiscontinuedCD34-mdr1 gene therapy(University of Michigan College of Engineering)
detail  >
OTL-101OTL-101Hematopoietic stem cell therapyImmune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Other DiseasesHematopoietic progenitor cell antigen CD34 modulators Stem cell replacementsOrchard Therapeutics PlcPhase 2/3OTL-101
detail  >
Anti-CD34 CAR-T (Shenzhen Geno-Immune Medical )Anti-CD34 CAR-T (Shenzhen Geno-Immune Medical )Autologous CAR-TNeoplasms Immune System Diseases Hemic and Lymphatic Diseases Other DiseasesHematopoietic progenitor cell antigen CD34 antagonistsShenzhen Geno-Immune Medical InstitutePhase 1Phase 1Anti-CD34 CAR-T (Shenzhen Geno-Immune Medical )
detail  >
Total 13 data
1
2